Livestock Pharmaceuticals (01513) announced the audited results for the year ended December 31, 2023. During the period...
According to the Zhitong Finance App, Lizhu Pharmaceutical (01513) announced the audited results for the year ended December 31, 2023. The group achieved operating income of 12.43 billion yuan (RMB, same below) during the period, a year-on-year decrease of 1.58%; net profit to the mother of 1,954 billion yuan, an increase of 2.32%; basic earnings per share of 2.1 yuan; and a proposed discovery dividend of 13.5 yuan per 10 shares.
According to the announcement, the Group's chemical products achieved sales revenue of 6.57 billion yuan during the year, a year-on-year decrease of 6.13%, accounting for 52.86% of the Group's revenue.
The Group continues to focus on new molecules and cutting-edge technologies in the field of global new drug research and development, focusing on the digestive tract, neuropsychiatric, assisted reproduction, and anti-tumor fields based on clinical value and differentiated forward-looking layout of innovative drugs and high-barrier complex formulations. During the reporting period, the company further improved its R&D innovation system, optimized the management structure of departments related to clinical management medicine and operation, and comprehensively covered multi-dimensional management such as medical research, clinical operation, and pharmacovigilance, and made phased progress in key pharmaceutical research projects. The details are as follows:
Complex preparations with high barriers such as microspheres: injectable tripraline acetate microspheres (1-month release) have been approved for marketing, phase III clinical trials for endometriosis have been completed and production data submitted to CDE; injectable aripiprazole microspheres (1-month sustained release) have been declared for production and registered for verification.
Other key research projects: injectable voriconazole (0.2g), new indications for injectable iprazole sodium (prevention of stress ulcer bleeding in critically ill patients), bunanserin tablets, and quetiapine fumarate sustained-release tablets were approved for marketing; rabeprazole sodium enteric tablets, progesterone injections, concentrated magnesium sulfate, sodium potassium oral solution, and terdizolamide phosphate for injection have been declared for production.
Key items for consistency evaluation: ciclosporin softgels, vancomycin hydrochloride for injection, and bismuth potassium citrate capsules have all been approved; bismuth potassium citrate granules and piropirone hydrochloride tablets have been declared.
In 2023, the company's API division continued to strengthen its work in various aspects such as EHS, quality, production, and sales to reduce costs and increase efficiency to seize the market. This year, the Group achieved sales revenue of 3.253 billion yuan for APIs and intermediates, an increase of 3.70% over the previous year, accounting for 26.17% of the Group's revenue.